Cardioprotection thread, page-783

As I discussed previously, not only does any other reformulation of bisantrene need to get around our existing granted reformulation patents, but the reformulation needs to offer clinical benefit over RC220 for it to be even ethical to run a clinical trial. Given what I know about reformulation and bisantrene's mechanism of action I don't think significant clinical improvement can be achieved via a different reformulation that we haven't already patented.

What is far more likely is a fast-follow, me-too drug with the same mechanism of action as bisantrene. Once you know what you want to achieve clinically you can throw a few dozen very talented chemists at the problem and they will develop you a new drug. While nobody can stop this from happening, we do have a plan to make this very, very difficult and time consuming to take any "new bisantrene" to approval.